Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016
Our recent RWE study detailed the comorbidity burden of Finnish multiple myeloma (MM) patients diagnosed between 2005 and 2016.
Welcome Tomi Vahevaara and Maija Wolf
Medaffcon’s growth has not slowed down in January. In the beginning of the month both our Medical Affairs team and our sales team gained reinforcements as Maija Wolf joined in as a Scientific Advisor and Tomi Vahevaara as Sales Director. Due to our continuing growth we also strengthened our administrative function welcoming aboard a new financial assistant Pauliina Punkari.
From 2008 onwards Maija Wolf has worked as a senior researcher at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, where she continues to work part-time. Maija has a strong background in cancer biology and molecular medicine with emphasis on resolving how cancer evolves and identifying novel therapeutic opportunities. Maija’s solid researcher background and expertise will greatly strengthen our RWE research team.
Tomi Vahevaara is already a seasoned expert in the pharmaceutical industry having over 35 years of experience. For the past ten years Tomi has worked as the Managing Director of Eli Lilly for Finland, Baltic States and Poland. He has gained wide-ranging experience in international expert and managerial positions within the innovative pharmaceutical industry. Tomi will no doubt ensure that Medaffcon’s growth will only accelerate!
